A Study on Hearing Profile in Hypothyroidism and Comparative Evaluation of Hearing in Hypothyroid Subjects before and After Treatment with Thyroxine – A Study of 100 Cases

Authors
Dr Harpuneet Kaur Bakshi1, Dr Dimple Sahni2, Dr J.P. Goyal3, Dr Raghuvansh Kumar4, Dr B.S. Sohal5, Dr Avnish Kumar6
1Junior Resident, 2,4Assistant Professor, 3,5Associate Professor, 6Professor
1,2,3 &5Department of ENT, 4Department of Endocrinology, 6Department of Physiology
Government Medical College, Patiala
Corresponding Author
Dr Dimple Sahni
94 Ajit Nagar, Patiala
Email: sawhneygirish@gmail.com

Abstract
Deafness is most common otolaryngological manifestation associated with thyroid dysfunction. So it was contemplated to study hearing profile in hypothyroid individuals and its response to thyroid hormone therapy.

Material Method- This original research study included 100 subjects divided into 2 groups. Case group included clinically and biochemically confirmed hypothyroid patients before treatment (n=50) Control group- included Euthyroid subjects (n=50)

Result: 41 out of 50 patients demonstrated hearing loss, 32 had Sensorineural hearing loss 9 had mixed hearing loss and 9 had normal hearing. Following treatment with levothyroxine hearing threshold improved by 5-10 db in 6 patients and more than 10 db in 33 patients while 2 patients had no improvement. BERA revealed reduced amplitude of wave I, II, III & V. After 6 months of treatment with levothyroxine wave V absolute amplitude improved significantly.

Conclusion: Hypothyroid patient had significant degree of hearing impairment. An improvement in hearing parameters occurred following levothyroxine replacement therapy over a period of 6 months.

Keywords – Hypothyroidism, BERA, thyroxine, Hearing loss, Audiometry.

Introduction
The thyroid hormones (T3 and T4) influence various metabolic activities in the body. It can be said that no tissue or organ system escapes the adverse effects of thyroid hormone insufficiency and the ear being no exception. In fact hearing loss may be the most common ENT manifestation of hypothyroidism.

Hypothyroidism both congenital and acquired has been associated with impaired hearing. It has been estimated that a significant hearing loss is found in 25% of patients with acquired hypothyroidism.1 Hypothyroidism effect 2% of adult women and only 0.2% of men.2-3 The pathophysiological mechanisms of hearing loss in hypothyroidism is not clear but it is known that in this hormonal
disorder there is a reduction in cell energy production, compromising the microcirculation, oxygenation and metabolism of the involved organs including. Inner ear structures such as the stria vascularis and organ of Corti. Although literature does not yield many studies on hearing changes in hyperthyroid patients.

The Objective of this study is to evaluate the prevalence of hearing impairment in hypothyroidism, correlation between severity of hearing impairment with serum TSH, T4 and T3 levels and to compare hearing thresholds before and after treatment with thyroxine.

Material and Methods
A prospective case control analytical type of study was conducted to evaluate hearing thresholds in hypothyroid patients and to compare these, before and after treatment with thyroxine hormone. The study was conducted in the Department of Otorhinolaryngology & Head and Neck Surgery and ENT Surgery Government Medical College, Rajindra Hospital, Patiala from 2012-2015 The study included 100 subjects, divided into two groups.

1. Case Group- Clinically and biochemically confirmed hypothyroid patients pre-treatment (n=50).
2. Control Group-Euthyroid subjects (n=50).

The Inclusion Criteria included age between 18 and 60 years and Proven cases of clinical hypothyroidism by history, clinical examination and hormone assays.

Exclusion Criteria included Age more than 60 years, patients with history of ear disease, Exposure to prolonged loud noise, family history of hearing impairment, history of intake of ototoxic drugs, history of head trauma and stroke and patients with diabetes mellitus. All the subjects on first reporting were tested for hearing impairment with puretone audiometry, impedance audiometry and BERA.

A comparison was performed between the hearing thresholds and brainstem evoked response audiometry parameters obtained from hypothyroid patients (Group-$ and normal subjects i.e. controls (Group 2), randomly selected and matching in age and sex with hypothyroid patients. The average of right and left ear was taken and analyzed.

Furthermore within Group I (hypothyroid patients), a comparison was performed between the hearing thresholds and brainstem evoked response audiometry parameters in the hypothyroid state and in the euthyroid state and after 6 months of treatment with thyroxine (Group I)

Evaluation of the data was carried out statistically by applying 'V' test for comparisons. 'p' value was calculated. 'p' value less than 0.05 and 0.005 were considered significant and highly significant respectively. A written and informed consent of the subjects were taken for the study.

Results
Of the 50 patients with hypothyroidism, 44 were females and 6 were males. Their age ranged from 18-60 years (mean 42.2 ± 12.814). (Table 1) 82% of the patients i.e. 41 out of 50 patients demonstrated hearing loss; 32 had sensorineural hearing loss, 9 had mixed hearing loss and 9 had essentially normal hearing. (Table 2)

The relationship between severity of hearing impairment and thyroid profile was found to be statistically insignificant. (p>0.05) (Table 3)

Following treatment with thyroxine, hearing thresholds improved by 5-10 dB in 6 patients and more than 10 dB in 33 patients at one or more of frequencies between 250-4000 Hz one or both of the ears while 2 patients had no improvement. A statistically significant improvement in hearing thresholds was observed by pure tone audiometry. (Table. 4)

Acoustic reflex tested at 1000 Hz at 105dB speech frequency was elicited in one or both ears in 21 hypothyroid patients only and no significant correlation could be made with post treatment results.

The Tympanogram was abnormal i.e. type B in 9 patients. Following treatment with thyroxine, Impedance audiometry curve i.e. tympanogram returned to type A in 7 out of 9 patients.
Brainstem electric response audiometry revealed delayed conduction along the brainstem indicated by prolonged absolute latency of wave V and interpeak latency IN and reduced amplitudes of waves I, II, III and V. (Table 5,6) Following treatment with thyroxine, brainstem auditory evoked response parameters did not show significant change towards normalcy following treatment except wave V absolute amplitude which improved significantly following 6 months of treatment with thyroxine. (Table 7,8)

| Table 1 Age & Sex Distribution of Patients & Controls |
|-----------------------------------------------|
| Age Groups in years | Study Group I | Control Group II |
|                   | Males | Females | Males | Females |
| 18-29             | 1     | 8       | 1     | 8       |
| 30-39             | 1     | 9       | 1     | 9       |
| 40-49             | 1     | 11      | 1     | 11      |
| 50-60             | 3     | 16      | 3     | 16      |

| Table 2 Pure Tone Audiometry |
|------------------------------|
| Frequency (Hz) | Hearing thresholds in dB | Pre-T/t Hypothyroid | Post – T/t Euthyroid | 'p' value |
| Controls | Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | 'p' value |
| 250      | 17.3 ± 6.79 | 23.2 ± 8.91 | 0.000 |
| 500      | 17.3 ± 5.07 | 22.8 ± 10.16 | 0.001 |
| 1000     | 17.6 ± 5.34 | 23.5 ± 11.83 | 0.002 |
| 2000     | 17.6 ± 6.87 | 29.4 ± 12.37 | 0.000 |
| 4000     | 19.5 ± 6.81 | 32.0 ± 13.823 | 0.000 |

| Table 3 Pure Tone Audiometry (Severity of hearing impairment) |
|---------------------------------------------------------------|
| Severity of hearing impairment | Moderate |
| Mean (Median) | IQR | Mean (Median) | IQR | 'p' value |
| S.T 3 | 0.70 (0.79) | 0.59-0.88 | 0.607 (0.70) | 0.36-0.78 | 0.084 |
| S.T 3 | 5.07 (5.3) | 4.8-5.7 | 4.49 (5.15) | 2.99-5.73 | 0.554 |
| S. TSH | 19.77 (14.6) | 9.8-27.08 | 27.18 (16.48) | 10.6-27.8 | 0.645 |

| Table 4 Pure Tone Audiometry |
|------------------------------|
| Frequency (Hz) | Hearing thresholds in dB | Pre-T/t Hypothyroid | Post – T/t Euthyroid | 'p' value |
| Controls | Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | 'p' value |
| 250      | 23.2 ± 8.91 | 17.00 ± 8.049 | 0.000 |
| 500      | 22.8 ± 10.16 | 16.35 ± 8.83 | 0.000 |
| 1000     | 23.5 ± 11.83 | 14.81 ± 9.05 | 0.000 |
| 2000     | 29.4 ± 12.37 | 19.50 ± 11.03 | 0.000 |
| 4000     | 32.0 ± 13.823 | 23.05 ± 13.73 | 0.000 |

| Table 5 Absolute latencies |
|-----------------------------|
| Waves | Absolute latencies in msec | Pre-T/t Hypothyroid | Post – T/t Euthyroid | 'p' value |
| Controls | Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | 'p' value |
| I | 1.6277 ± 0.17673 | 1.6600 ± 0.11416 | 0.216 |
| II | 2.7722±0.14341 | 2.7159±0.12006 | 0.60 |
| III | 3.6908±0.24796 | 3.7421±0.17732 | 0.118 |
| IV | 5.6846±0.30323 | 5.6626±0.23368 | 0.604 |

| Table 6 Inter – Peak latencies |
|--------------------------------|
| Inter-peak latencies | Controls | Post – T/t hypothyroid | 'p' value |
| Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | 'p' value |
| I-II     | 1.9513±0.25928 | 2.0161±0.27229 | 0.216 |
| III-IV   | 1.8505±0.27620 | 1.8935±0.18900 | 0.404 |
| I-V      | 3.8030±0.30470 | 3.9619±0.23224 | 0.005 |

| Table 7 Absolute wave amplitudes |
|---------------------------------|
| Waves | Absolute wave amplitudes (µV) | Controls | Post – T/t hypothyroid | 'p' value |
| Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | 'p' value |
| I | 0.3769 ± 0.13882 | 0.2675 ±0.08994 | 0.000 | 0.000 |
| II | 0.3471 ± 0.20775 | 0.1875±0.11891 | 0.000 | 0.000 |
| III | 0.4419±0.19657 | 0.2803±0.13309 | 0.000 | 0.000 |
| IV | 0.5792±0.15492 | 0.3406±0.14061 | 0.000 | 0.000 |

| Table 8 Absolute wave amplitudes |
|---------------------------------|
| Waves | Absolute wave amplitudes (µV) | Controls | Post – T/t euthyroids | 'p' value |
| Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | 'p' value |
| I | 0.2675±0.08994 | 0.2279±0.10046 | 0.042 | 0.000 |
| II | 0.1875±0.11891 | 0.2177±0.14736 | 0.180 | 0.000 |
| III | 0.2803±0.13309 | 0.3040±0.17972 | 0.339 | 0.000 |
| IV | 0.3406±0.14061 | 0.3912±0.15043 | 0.044 | 0.000 |
Discussion

In the present studies hearing impairment in the hypothyroid patients was observed in 41 out of 50 patients (82%). The nature of hearing loss was predominantly sensorineural (32 out of 41 patients). The remaining 9 patients exhibited mixed loss. The hearing loss was mild to moderate, with none of the patient exhibiting severe loss. Improvement in hearing thresholds following 6 months of replacement therapy was observed in 39 out of 41 patients.

The presence of a significant difference in the hearing thresholds of hypothyroid patients when compared to an age and sex matched control group was taken as reasonable evidence of a causal relationship between hypothyroidism and hearing loss. In addition, a significant difference in the hearing thresholds was found following replacement therapy with thyroxine, indicating an improvement in the hearing sensitivity with levothyroxine.

Our findings are thus in total agreement with those of Vant Hoff who had reported an incidence of 85% hearing impairment in 48 myxoedematous patients and improvement in 73% after treatment with levothyroxine. The results of our study also support previous studies by Howarth & Lloyd, Hilger, Anand et al, Brucker-Davis F et al, and Orhan et al.

No relationship was found between severity of hearing impairment and thyroid profile. This is in contrast to Malik et al who observed hearing impairment to increase with increasing serum TSH levels and decreasing T3 and T4 levels (p>0.05).

The functional integrity of the auditory pathway depends on the intact anatomical pathway, functional relay stations, myelination and thickness of the tract and absence of any compression or pressure from outside. BAEP (Brainstem Auditory Evoked Potentials) have come into widespread use for the assessment of the clinical state of the middle portion of the brainstem. It allows evaluation of functional integrity of auditory pathway from hair cells to thalamic nuclei. Values of BAEP (particularly the absolute and interpeak latencies) represents the peripheral (from acoustic nerve and pontomedullary portion) and central (pontomesencephalic) conduction time.

In our study, Brainstem electric response audiometry revealed delayed conduction along the brainstem indicated by prolonged absolute latency of wave V and interpeak latency I-V and reduced
amplitudes of waves I, II, III and V. Thus the brainstem electric response parameters in hypothyroidism were 'slow and low' as compared to those obtained from controls. Similar to this, Abbott et al.,\textsuperscript{13} reasoned that diminished myelin production and alteration in cerebral metabolism during acute hypothyroidism may be the possible explanations for the reduction of wave I, V amplitudes. Huang et al\textsuperscript{14} reported increased absolute latency and interpeak latencies in a study conducted on 16 hypothyroid patients. Anand et al\textsuperscript{8}, in a study on 20 hypothyroid subjects, observed prolonged absolute latency of wave V and prolonged interpeak latencies I-III and IN and reduced absolute amplitudes of waves I, II and V. Lorenzo et al\textsuperscript{15} reported in 25% of the hypothyroid patients, increase in wave V absolute latencies and that of inter-peak latencies III-IV and IN. Khedr et al\textsuperscript{16} in a study on 23 hypothyroid patients, reported prolongation of all wave latencies and interpeak latencies in some of the patients. Yumnan Anjana et al\textsuperscript{17}, in a study on 30 patients, observed reduced amplitude of wave V which supports our result but reported prolongation of absolute latency of wave III and interpeak latencies I-III, which is in contrast to our study. Our results are also in partial agreement with that of Thornton and Jarvis\textsuperscript{18} who reported reduced absolute amplitudes of waves I and V and prolongation of interpeak latency I-V, suggesting retrocochlear defect. Chandrashekhar et al\textsuperscript{19} also observed prolonged absolute latencies in waves III and V and interpeak latency I-V and reduced absolute amplitude I and V.

The above observations probably indicate that the site of lesion in hypothyroid hearing loss is at multiple levels in the auditory system; in the middle ear, cochlea and retrocochlear sites. Although a definitive subjective improvement in hearing was documented in post-treatment audiograms but brainstem evoked response parameters did not show significant reversibility to normalcy except in wave V absolute amplitude which showed statistically significant improvement with 6 months of thyroxine therapy. Similar to these, Anand et al\textsuperscript{8} and Di Lorenzo et al\textsuperscript{15} also reported no statistically significant improvement in these parameters after 6-12 months of treatment with thyroxine. Our result is in partial agreement with Abbott et al\textsuperscript{13}, who reported decreased amplitudes of waves I and V and reasoned that diminished myelin production and alteration in cerebral metabolism during acute hypothyroidism may be the possible explanations for the reduction of wave I, V amplitudes, which can be reversed after treatment.

In contrast to our results, Chandrasekhar et al\textsuperscript{19} observed that there was a significant prolongation of wave III and V latency in hypothyroid patients without treatment and significant increase in wave III and V latency in hypothyroid patients with TH treatment. In the IPL of BAEP, there was a significant prolongation of IPL I-V in hypothyroid patients without treatment and significant increase in hypothyroid patients with TH treatment. Also, there was significant reduction in amplitudes I-Ia and V-Va in hypothyroid patients without treatment and significant increase in amplitudes I-Ia and V-Va in hypothyroid patients with treatment.

Neurotransmitter system and axonal transportation. Knipper et al\textsuperscript{20} in his study discussed that the TH can accelerate gene expression not only in oligodendrocytes but also in schwann cells of the auditory tract, leading to an improved understanding of the role of TH in the process of myelin genesis. He also explained that the auditory system nerve conduction and impulse transmission from the cochlea to the brainstem can occur coincidently with initial transduction of sound signals only in the presence of TH.

Normal levels of thyroid hormones are required for proper excitability of the peripheral auditory pathway, thalamo-cortical projections and auditory processing at the cortical level. So, the changes in BAEP could be multi etiological factors such as low body temperature, alteration in cerebral metabolism, myxoedematous infiltration, defective myelination and regulator proteins like...
"otoferlin" and "prestin" which is entirely depend upon the metabolic action of thyroxine hormone. However, significant improvement in absolute amplitude of wave V may indicate that there is a better recruitment of neuronal pool of the generators of these waves of BERA in the brainstem which may further go in favour of hearing improvement.

Conclusions
The hypothyroid patients demonstrate a significant degree of hearing impairment when compared to age and sex matched normal subjects. The site of lesion in auditory system is probably at multiple levels; in the middle ear, cochlea and retrocochlear sites. As a significant improvement in hearing parameters occurred following levothyroxine replacement therapy, so conclude a relationship between hearing loss and hypothyroidism. As changes were noted in BERA parameters and significant improvement seen in absolute amplitude parameter of wave V. so there might be a slow conduction at the periphery and with treatment, there is a better recruitment of neuronal pool of the generators of the waves of BERA in brainstem In conclusion, hypothyroidism may lead to alteration in auditory pathway n central nervous system as determined by BERA recordings. So brainstem auditory evoked potential could be useful to evaluate the effect of hypothyroidism on auditory pathway and central nervous system. The Tympanogram was abnormal i.e. type B in 9 patients. Following treatment with thyroxine, Impedance audiometry curve i.e. tympanogram returned to type A in 7 out of 9 patients.

Conflict of interest- None
Source of funding - Nil

Bibliography
1. Vanasse M, Fisher C, Roux Y, Volman G, Mornex R. Normal brainstem auditory evoked potential in adult hypothyroidism. Laryngoscope. 1989;99:302-6.
2. Freitas MC, Lima LHC. Diagnostico e tratamento do hipotireoidismo. In Vilas L, editor. Endocrinologia Clinica. Guanabara koogan; 2006.p.219-30.
3. Jaime JC. Auto-immunidale endocrina. In: Greenspan FS & Gardner DG, editors. Endocrinologia Basica e Clinicia. 7 ediae. Rio de Janeiro: Mc Graw-Hill I nteramericana do Brasil;2006. p.71-87.
4. Oliveira JAA. Fisiologia de Audiocaco-Coclea ativa In: Figueiredo MS. Emissos Otoacousticas e BERA Sao Jose dos Campos; Pulso Editorial; 2003 p.1-34.
5. Vant Hoff W, Stuard DW, Deafness in myxoedema. OJ Med.1979; 48:361-7.
6. Howarth AF, Lloyd HE. Perceptive deafness in hypothyroidism. British Medical Journal. 1956;1:431-33.
7. Higler JA. Otolaryngologic aspects of hypometabolism. Ann Otol Rhinol Laryngol. 1956; 65:395-413
8. Anand VT, Mann SB, Dash RJ, Mehta YN. Auditory investigations in hypothyroidism. Acta Otolaryngol (Stockh). 1989; 108:83-87.
9. De Vos JA. Deafness in hypothyroidism journal of Laryngology and Otology 1963;77:390-414.
10. Malik V, Shukla GK, Bhatia N. Hearing profile in hypothyroidism. Indian Journal of Otolaryngology and Head and Neck Surgery. 2002 Dec;54:285-90.
11. Aggarwal Mk, Singh GB Nag RK, Singh SK, Kumar R, Yadav M. Audiological evaluation in goitrous hypothyroidism international journal of otolaryngology and Head & Neck Surgery. 2013 Sept;2(5): 201-206.
12. Berker D, Karabulut H, Isik S, Tutuncu Y, Özuguş U, Erden G, et al. Evaluation of hearing loss in patients with Graves' disease. Endocrine 2012;41:116-21
13. Abbott RJ, O'Malley BP, Barnett DB, Timson L, Rosenthal FD. Central and peripheral nerve conduction in thyroid
dysfunction: The influence of L-thyroxine therapy compared with warming upon the conduction abnormalities of primary hypothyroidism. Clinical Science. 1983 Jun; 64(6):617-22.

14. Huang TS, Chan YC, Lee SH, Chen FW, Chopra JJ. Visual, brainstem auditory and somatosensory evoked potential abnormalities in thyroid disease. Thyroidology. 1989 Dec; (3): 137-42.

15. Di Lorenzo L, Foggia L, Panza N, Calabrese MR, Motta G, Granchino G, Orio F Jr, Lombardi G. Auditory brainstem response in thyroid diseases before and after therapy. Horm Res. 1995;43(5):200-5

16. Khedr EM, El Toony LF, Tarkhan MN, Abdella G. Peripheral and central nervous system alterations in hypothyroidism: electrophysiological findings. Neuropsychobiology.2000 Jan;41(2):88-94.

17. Yumnan Anjana, Neelam Vaney, Tandon O P, Madhu S V. Functional status of auditory pathway in hypothyroidism, Evoked potential study. Indian Journal of Physiology and Pharmacology.2006;50:341-349

18. Thornton A R D, Jarvis S J. Auditory brainstem response findings in hypothyroid and hyperthyroid

19. Chandershekhar M, Kowsalya V, Vijayalakshmi B. Electrophysiological changes on brainstem auditory evoked potentials in hypothyroid patients journal of pharmacy Research 2011;4(8):2856-2859.

20. Knipper M, Bandtlow C, Gestwa L, Kopschall I, Rohbock K, Wiechers B, Zermer HP, Zimmermann U. Thyroid hormone affects schwann cell and oligodendrocyte gene expression at the glial transition zone of the VIIIth never prior to cochlear function. Development. 1988 Sep; 125 (18): 3709-18.

21. Orhan I, Palit F, Aydin S, Soyle E, Sakalioglu O. Tympanometric changes and Eustachian tube function in patients with hypothyroidism. J craniofac Surg. 2014 May ; 25(3)e230-3.

22. Brucker-Davis F, Skarulis MC, Pikus A, Ishizawar D, Mastroianni MA, Koby M, Weintraub BD. Prevalence and mechanisms of hearing loss in patients with resistance to thyroid hormone. J Clin Endocrinol Metab. 1996 Aug;81(8): 2768-72